Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.

J, Rosenstock; R, Emral; L, Sauque-Reyna; V, Mohan; C, Trescolí; Sifri S, Al; N, Lalic; A, Alvarez; P, Picard; M, Bonnemaire; N, Demil; RJ, McCrimmon

doi:10.2337/dc21-0393

Public

Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.

Shared by NobleBlocks on Jun 28, 2021 • 12:00 AM UTC

Authors:

Rosenstock J

Emral R

Sauque-Reyna L

Abstract

<h4>Objective</h4>To directly compare the efficacy and safety of a fixed-ratio combination, of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi), with those of a premix insulin analog, biphasic aspart insulin 30 (30% insulin aspart and 70% insuli...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!